MedTrace Logo

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

NCT00707473 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-03-05

No results posted yet for this study

Summary

This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
  • Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
  • Sinonasal Undifferentiated Carcinoma
  • Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
  • Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8
  • Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8
  • Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8

Interventions

DRUG

Carboplatin

Given IV

OTHER

Chemoradiotherapy

Undergo chemoradiotherapy

DRUG

Cisplatin

Given IV

PROCEDURE

Definitive Surgical Resection

Undergo surgery

DRUG

Docetaxel

Given IV

DRUG

Fluorouracil

Given IV

PROCEDURE

Quality-of-Life Assessment

Correlative studies

RADIATION

Radiation Therapy

Undergo radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Ehab Y Hanna · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-16
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707473 on ClinicalTrials.gov